Duloxetine and pregabalin in neuropathic pain of lung cancer patients
Küçük Resim Yok
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
John Wiley and Sons Ltd
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Introduction: Neuropathic pain occurs in 1% of the population and is difficult to manage. This chronic pain causes psychological distress and impacts patient's quality of life, especially in cancer patients. The aim of this study was to show and compare the efficacy of pregabalin and duloxetine, which are reported in the group of first-line treatment at European Federation of Neurological Societies (EFNS) guidelines on the pharmacological treatment of neuropathic pain (2010 revision) in lung cancer patients by using visual analogue scale (VAS) and Leeds Assessment of Neuropathic Symptoms and Sign (LANSS). Patients and Methods: A prospective, randomized, open label, 3 month of study was conducted. A total of 44 patients that were diagnosed with neuropathic pain (14 women and 30 men) were included in the study. Patient's LANSS and VAS values were recorded before treatment. Then, 22 patients undergo pregabalin and 22 patients undergo duloxetine therapy. But due to side effects (dizziness, constipation), two patients had stopped to use pregabalin. Their LANSS and VAS values were recorded after 1 and 3 months of therapy. Results: When we compare LANSS and VAS scores before treatment, after 1 and 3 months of treatment with pregabalin and duloxetine, a significant decrease was observed in both groups at the 1 and 3 months (p <.01). Duloxetine is superior to pregabalin in reducing the LANSS scores when we compare two groups. Conclusions: Both duloxetine and pregabalin are effective in the treatment of neuropathic pain of lung cancer patients. And as far as we know, this is the first study comparing the efficacy of duloxetine and pregabalin in the neuropathic pain of lung cancer patients. © 2020 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
Açıklama
Anahtar Kelimeler
cancer, duloxetine, efficacy, neuropathic pain, pregabalin, duloxetine, pregabalin, analgesic agent, duloxetine, pregabalin, adult, aged, Article, cancer patient, clinical article, comparative effectiveness, constipation, controlled study, dizziness, female, human, lung cancer, male, neuropathic pain, open study, practice guideline, prospective study, randomized controlled trial, visual analog scale, cancer pain, complication, lung tumor, middle aged, neuralgia, pain measurement, quality of life, treatment outcome, very elderly, Adult, Aged, Aged, 80 and over, Analgesics, Cancer Pain, Duloxetine Hydrochloride, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neuralgia, Pain Measurement, Pregabalin, Prospective Studies, Quality of Life, Treatment Outcome
Kaynak
Brain and Behavior
WoS Q Değeri
Scopus Q Değeri
Q2
Cilt
10
Sayı
3
